Stock events for Merit Medical Systems, Inc. (MMSI)
Over the past six months, Merit Medical Systems's stock price has experienced a decline, trading at the lower end of its 52-week range. Key events impacting the stock include the Q3 2025 earnings report, which showed a revenue increase of 13.0% year-over-year. The WAVE Trial efficacy results were reported, with the WRAPSODY CIE achieving a 6-month TLPP of 81.4%. The Q4 2025 earnings report and FY2026 guidance were released, with the company announcing better-than-expected revenue but a non-GAAP profit below analysts' estimates. The Chief Operating Officer notified an intention to sell stock. MMSI underperformed the US Medical Equipment industry and the broader US Market.
Demand Seasonality affecting Merit Medical Systems, Inc.’s stock price
While specific detailed information on demand seasonality for Merit Medical Systems's products and services is not explicitly provided, the demand for medical devices is generally driven by healthcare needs and patient volumes. These can be influenced by factors such as elective procedure scheduling and budget cycles of healthcare facilities. The critical nature of many of Merit Medical's products suggests a relatively stable demand less prone to extreme seasonality. The company's diverse product portfolio across various medical specialties also helps to mitigate significant seasonal swings.
Overview of Merit Medical Systems, Inc.’s business
Merit Medical Systems, Inc. (MMSI) is a global manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, operating in the Healthcare sector, specifically in the Medical Instruments & Supplies industry. The company's product portfolio is divided into Cardiovascular and Endoscopy segments. The Cardiovascular segment includes devices for peripheral and cardiac intervention, custom procedural solutions, and OEM products. The Endoscopy segment focuses on gastroenterology and pulmonary products, including esophageal stents and balloon dilators. Merit Medical distributes its products through a direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers to hospitals and alternate site-based providers.
MMSI’s Geographic footprint
Merit Medical Systems maintains a significant global presence, spanning North America, Western Europe, Australia, Asia-Pacific, and emerging markets including Brazil and India. The company sells its products in the United States, China, Japan, Germany, France, the United Kingdom, Canada, Malaysia, South Korea, the United Arab Emirates, New Zealand, and South Africa. It has distribution centers and sales offices across North America, Europe, the Middle East, Africa, Asia, and Latin America.
MMSI Corporate Image Assessment
Merit Medical Systems has a reputation as a prominent player in the healthcare sector, known for its innovative single-use medical products. The company emphasizes innovation, quality, and customer education. Positive clinical trial results for the WRAPSODY Cell-Impermeable Endoprosthesis (CIE) and subsequent regulatory approvals enhanced its reputation. Portfolio expansion through acquisitions, such as the C2 CryoBalloon device, positively impacted brand reputation. Strong financial performance, as seen in Q4 2025, contributes to a strong financial reputation.
Ownership
The ownership structure of Merit Medical Systems (MMSI) stock is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion, approximately 59.60% to 84.27% of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. The largest individual shareholder is Fred P. Lampropoulos, President and CEO, owning approximately 1.43 million shares, representing 2.40% of the company. Other principal insider shareholders include Director A Scott Anderson and Chief Commercial Officer Joseph Wright.
